• Mydecine plans to launch a program to provide products and services to healthcare professionals, clinics, and hospitals in Canada looking to treat patients through psychedelic-assisted psychotherapy
• The products and services, which will be available for purchase as a package, include cGMP psilocybin and MDMA, therapy manuals, investigative brochures, protocol training, advisory services, and post-therapy support
• The planned launch follows an amendment to federal regulations allowing physicians to request and prescribe restricted drugs for treatment-resistant patients

Canada began the year on a high note by updating the Special Access Program (“SAP”), a move that demonstrates the government’s serious consideration of the potential of restricted substances to treat a range of conditions. The update removes a previous prohibition enacted in 2013 that outlawed the access of restricted drugs through the SAP. Starting this month, healthcare professionals can request patient access to restricted drugs, listed in Schedules I – V of the Controlled Drugs and Substances Act (“CDSA”), for treatment of life-threatening or serious conditions when other therapies have proven unsuccessful, are unavailable in Canada, or unsuitable. MDMA (more commonly known as ecstasy) and psilocybin are among the drugs patients can access through the updated SAP (https://ibn.fm/aFu31). As a direct response to the change, Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company looking to transform the treatment of mental health and addiction disorders, on January 13 announced plans to launch The Special Access Support and Supply Program (“SASSP”). The program is intended to fill a critical void created by the update by providing products and services to thousands of physicians, clinics, and hospitals looking to treat patients through psychedelic-assisted psychotherapy (https://ibn.fm/O7CFD). In addition, the SASSP will offer A-Z support to medical practices across Canada, re-enforcing the safety and effective integration of psychedelic-based treatments. As part of the program, healthcare professionals can purchase a package that includes cGMP psilocybin and MDMA, therapy manuals, investigative brochures, protocol training, advisory services, and post-therapy support for patients through Mindleap Health, Mydecine’s wholly-owned subsidiary. Mydecine is currently producing cGMP certified pharmaceutical grade psilocybin and MDMA with coverage under a Health Canada Schedule 1 Drugs and Substances Dealer’s License in Alberta. Through the SASSP, the company believes it can help treat a significant patient population who need alternative treatment options for mental illnesses, particularly in cases where they have not responded to available evidence-based treatments. Notably, treatment resistance affects 20-60% of patients with mental illnesses/disorders (https://ibn.fm/QCeFp). With the Mental Health Commission of Canada noting that one in five people live with mental illnesses every year (about 7.6 million people today, based on the country’s population), treatment resistance indeed afflicts a significant population (https://ibn.fm/9ZNUN). “By launching this program, we are providing the resources the thousands of non-psychedelic clinics and hospitals will need in order to safely and effectively integrate these therapies into existing medical practices,” stated Mydecine CEO Josh Bartch. A 2016 study published in the Journal of Psychopharmacology and considered one of the first in the current psychedelic renaissance era established that a single dose of psilocybin lowered the rate of depression by 78% and anxiety by 83% six months after subjects had received treatment (https://ibn.fm/jJn12). Since then, numerous other studies have been conducted. A 2020 Johns Hopkins University study, for instance, showed that psilocybin with supportive psychotherapy relieves major depression, with half of study participants achieving remission through the four-week follow-up (https://ibn.fm/TnktS). Psilocybin has also been evaluated as a potential treatment for Post-Traumatic Stress Disorder (“PTSD”). A 2020 study found that “participants seemed to improve over time with respect to their symptoms of both PTSD and complicated grief” (https://ibn.fm/THVQv). Mydecine is also planning a Phase 2A clinical trial focusing on PTSD in front-line and emergency medical service (“EMS”) workers and veterans. This study will use the company’s lead drug candidate, MYCO-001, which is made up of 99% pure psilocybin. Relatedly, a 2021 study demonstrated that “MDMA-assisted therapy is highly efficacious in individuals with severe PTSD, and treatment is safe and well-tolerated, even in those with comorbidities,” concluding that MDMA-assisted therapy “represents a potential breakthrough treatment.” For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• In 2021, Delic’s investments and acquisitions allowed for an annualized revenue run-rate of over $9MM
• Going into the new year, the company looks forward to opening additional ketamine infusion treatment clinics, growing them by 15 within the next 18 months
• Delic’s growth has been attributed to the strong demand for alternatives to current treatments for mental health conditions
• Its management is confident that the foundations laid down so far position Delic for growth and profitability in 2022 and beyond

2021 was an excellent year for Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), as indicated in the company’s recent update (https://ibn.fm/HokJs), marked by key acquisitions and furthering its goal of providing the highest standard of care to patients. According to the management team, these achievements position the company well for growth and profitability in 2022 and beyond. In November 2021, Delic closed the acquisition of Ketamine Wellness Centers (“KWC”), an enterprise that operated 10 ketamine infusion treatment clinics across the United States (https://ibn.fm/K3Vug). The purchase brings the total number of operational Delic clinics to 12, making it the largest chain of wellness centers providing ketamine treatments in the United States. Delic is also confident that within the next 18 months, there will be 15 more clinics in operation, ultimately sealing its position as the undisputed leader in the segment. “At Delic, we have built the most profitable model for scaling the best-in-class care directly to patients through the largest network of mental health clinics in the U.S.,” noted Matt Stang, the Co-founder and Chief Executive Officer (“CEO”) of Delic. All acquisitions for the 2021 financial year were geared towards accelerating Delic’s growth trajectory and establishing its self-sustaining ecosystem of businesses that currently comprises Ketamine Infusion Centers (“KIC”), Delic Labs, KWC and a number of media properties. In total, these investments allowed for the company to realize an annualized revenue run-rate of over $9MM, a figure which the company is confident will be surpassed in 2022. Matt Stang, the Co-founder and Chief Executive Officer of Delic, has been keen to note that the company’s success has been primarily driven by the growing demand for alternatives to mainstream treatments for mental health conditions influenced by the ongoing pandemic. “We are seeing a strong demand for alternatives to current treatments with lasting outcomes and less side effects,” Mr. Stang noted. Delic’s media properties, including Meet Delic, arguably the world’s largest annual psychedelic wellness event, also demonstrate the power of the Delic ecosystem of businesses. In November 2021, it attracted over 2,500 attendees and over 2,000 inbound calls to clinics in a span of two days. Through achievements such as these, coupled with the company’s aggressive expansion and rollout, Delic is differentiating itself, with management confident in growth and profitability in 2022 and beyond. For more information, visit the company’s website at www.DelicCorp.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• Eat Well Group has engaged Avenue7Media, a leading digital merchandising agency, to develop the online snacking platform for Eat Well Group portfolio products
• The platform, scheduled for delivery in Spring 2022, will help Eat Well grow its portfolio investment, brands, and consumer products, through Amazon.com
• The snacking culture has grown over the last few years, and e-commerce has offered a convenient avenue to shop for snacks
• Eat Well Group has also engaged several other service providers as it looks to expand its North American and European digital and market awareness campaigns

Over the recent years, a growing number of people have preferred snacking to taking a full meal. In 2019, for instance, 59% of global adults opted to eat many small meals spaced throughout the day, instead of a few large meals, according to a report (https://ibn.fm/vC6Fx). The figure grew even more in 2020, with The State of Snacking in 2020 report detailing that 88% of global adults say they are snacking more than before. The pandemic is cited as the leading cause of the uptick, with other reasons being the reduced cost of snacks compared to full meals, which made snacks a substitute food, and their utility as a supplement in between meals (https://ibn.fm/XTb9S). As the COVID-19 pandemic ravaged the world, forcing people into isolation, comfort became a priority. Many people began buying snacks due to nostalgia or because snacking brought them moments of peace and brightened their day. It was also considered a remedy for loneliness. Accordingly, this demand spawned increased e-shopping. For instance, roughly half (47%) of global adults started to purchase snacks online more often than they did offline, 69% of whom say they would extend this trend post-pandemic. To tap into this burgeoning demand for snacks, vertically integrated plant-based foods company Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) has engaged Avenue7Media (“Ave7”) as its lead Amazon digital merchandising agency. Ave7, which in fact established, through its proprietary technology stack, that online snack sales continue to grow 3-5x the offline sales rates, will focus on the growth of Eat Well’s portfolio investments, brands, and consumer products, through Amazon.com (https://ibn.fm/koT2b). Specifically, Ave7 will develop the online snacking platform for Eat Well Group’s portfolio products, including Sapientia Technologies’ “plant-based Cheeto” and Amara Organic Baby Foods shelf-stable products, with delivery in Spring 2022. The platform will aim to exploit the efficient and powerful distribution capabilities of e-commerce. “The team at Avenue7Media are operators with a digital merchandising mindset,” commented Eat Well Group CEO and Director Marc Aneed. “We chose to partner with them because they understand Amazon from the technology, shopping behavior, financial, and logistics angles simultaneously. We can’t wait to drive significant growth for years to come.” Jason Boyce, Founder and CEO of Ave7, expressed his enthusiasm at the growth potential for Eat Well Group’s investment portfolio of snacks online, further noting that “With the snack market being a multi-billion-dollar sector, plant-based good-for-you snacks can become dominant online.” Analysts at Mordor Intelligence estimate that the global snack food market, which was valued at $427.02 billion in 2020, will grow at a CAGR of 3.37% between 2021 and 2026 (https://ibn.fm/KuLU5). Citing the increased demand occasioned by the pandemic, the report underlines that the convenience and portability of snacks have propelled their increased consumption. “Convenience is also driving online sales of ready-to-eat snacks, with snack foods being one of the top food categories purchased through the e-commerce channel,” it highlights. For more information, visit the company’s website at www.EatWellGroup.com. NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://ibn.fm/EWGFF

• Plant-based lifestyle brand builder PlantX Life Inc. offers more than 5,000 plant-based products through meal and indoor plant deliveries, and the company is working through research and development to introduce new product categories in the coming year
• PlantX is also adding to its physical XMarket store locations, advancing from initial British Columbia and California outlets to new locations in Ontario (Toronto and Ottawa), with further XMarket brand transition under way at stores in the Chicago area of Illinois
• The company is also preparing to open a new store and e-commerce presence in Tel Aviv, Israel this month as part of its first global endeavor outside of North America
• The XMarket physical retail locations have the primary role of enhancing the company’s e-commerce capabilities by acting as fulfillment centers that the company can use to improve its distribution infrastructure and better serve its online customers
• PlantX recently announced the election of directors and the appointment of new auditors to shareholders as further development of its strategy for the new year

Consumer trends indicate the demand for plant-based proteins as an alternative to animal products is growing at a tremendous pace, with a CAGR of 9.7 percent anticipated between 2021 and 2028 to produce revenues of $23.4 billion, according to industry analysts at Research and Markets. “The growth of this market is mainly attributed to the growing demand for protein-rich diet, growing health & wellness trend, increasing consumers’ focus on meat alternatives, growing demand from the food & beverage industry, and various advancements in ingredient technologies such as microencapsulation are the key factors driving the growth of the plant-based protein market,” the report states (https://ibn.fm/Edblk). Progressive plant-based lifestyle platform builder PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) marked 2021 as a growth year as it added retail outlets to strengthen its vision of becoming a one-stop shopping and education hub for all plant-based community interests, such as those expressed in the Research and Markets forecast, as PlantX grows toward 86 planned store locations to be opened by the end of this year in support of its e-commerce platform (https://ibn.fm/9em1W). It’s an ambitious goal for a company still in the beginning phases of its brick-and-mortar openings. PlantX is a Vancouver, British Columbia-based Canadian entity that partnered with chef Matthew Kenney of Matthew Kenney Cuisine to establish the company’s XMarket branded stores last year in British Columbia, Southern California (Los Angeles and San Diego areas), and Ontario (Toronto and Ottawa), with two locations set to rebrand as XMarket in Illinois (Chicago area) as well as a new store opening expected this month in Israel (Tel Aviv). Each of the physical store locations serve local plant-based communities, but their primary role will be to establish an extensive network of fulfillment centers for PlantX’s e-commerce operations. As the network of XMarket stores grows, the strength of PlantX’s distribution infrastructure will grow as well, enhancing the company’s ability to serve its customers in regions throughout North America and around Israel. Recently, PlantX made an important announcement – the debut of its innovative XMarket café and store at Hudson’s Bay Rideau in Ottawa — Canada’s capital city in southeast Ontario. The 100 percent plant-based café features carefully-crafted vegan beverages and plant-based food options with ingredients sourced from Ottawa businesses, including local bakery Keepin’ it Vegan (https://ibn.fm/RKhzS). The company also announced the results of a general meeting of shareholders, including the election of directors and the appointment of new auditors for the ensuing year (https://ibn.fm/vaHKf). The company’s recent acquisition of plant-based market and e-commerce platform Peter Rubi has provided PlantX its physical store locations in the Chicago area of the United States, which it plans to convert to XMarket locations in the near future (https://ibn.fm/xkruY). Peter Rubi’s warehousing assets will benefit PlantX’s fulfillment and distribution infrastructure in the U.S. Midwest as the company continues to grow. PlantX became a seller on the Walmart Marketplace last year, offering more than 500-plant based grocery products through the global retailer’s massive reach to consumers. Overall, PlantX offers customers across North America more than 5,000 plant-based products through meal and indoor plant deliveries, and the company is preparing to expand its product lines to include cosmetics, clothing, personal care and its own water brand, underscoring the importance of a strong fulfillment infrastructure. The company recently announced the expansion of its online operations to include discounts for shoppers who subscribe for recurring service, and it is contracting with social media “micro-influencers” to help build the PlantX brand. Its website’s educational efforts include community-focused information shared through a weekly podcast, YouTube channel and blog. Bloomberg Intelligence analysts valued the overall global market for plant-based foods and products, including the plant-based protein market mentioned earlier, at $29.4 billion in 2020. The analysts predicted revenues will exceed $162 billion by 2030, which would be an astronomical increase of 451 percent (https://ibn.fm/DBeYw). For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• U.S.-based communications technology brand FingerMotion is building its profits as it focuses on services for China’s world-leading, mobile-connected population
• FingerMotion recently reported its financial statement for the Q3 quarter ending Nov. 30, noting gross profits at a record $967,075
• The profits report was 56 percent higher than the same period during the previous year, driven primarily by the company’s Telecommunications Products and Services business
• FingerMotion’s Telecommunications Products and Services revenues grew 580 percent YOY despite a slowing trend for SMS services as the company shifted resources to the company’s collaboration with China Mobile in the country’s Fujian province for 5G-related SMS products

Evolving communications and big data technology company FingerMotion (NASDAQ: FNGR), is entering 2022 with record profitability and continued growth of its gross margins. “We expect this trend in gross margins to continue, and revenue should ramp as the insurtech business starts to unfold,” CEO Martin Shen stated in conjunction with the company’s announcement Jan. 18 of its financial profile for the third quarter ended Nov. 30 (https://ibn.fm/ypswa). “During the past quarter the company announced the formation of two new brands in order to provide mobile device protection in China. Beta testing is underway and could start contributing to revenue in the current quarter. The company anticipates this could represent a significant revenue stream in the next fiscal year.” FingerMotion reported its gross profit reached a new record of $967,075 during the quarter, driven by revenues of $5.9 million. That marked a 21 percent increase year-over-year in the revenue report, with the gross profit 56 percent higher YOY. The bulk of the revenue optimism came from the company’s Telecommunications Products and Services business, which grew 580 percent ($2.8 million) over the previous year’s Q3 report. The company’s Big Data analysis division, Sapientus, reported its first revenues last year and is expected to eventually be the leading revenue generator for FingerMotion as it enters the market for insurtech services. The division did not report any revenue for Q3, but the company continues to devote “considerable time … on continuing discussions with Pacific Life Re, the global life reinsurance company” that was the first company to contract with FingerMotion for big data services, Shen stated. FingerMotion is a China-focused company specializing in mobile technology services. The Asian nation contains nearly 1.5 billion mobile users and analysts at Reportlinker.com anticipate that mobile engagement in China will continue to grow in the years to come, achieving a CAGR of 44.7 percent between 2020 and 2027 for revenues of $22.4 billion by the end of the forecast period. That’s about a quarter of the analysts’ entire global forecast for the period. Shen states FingerMotion is particularly focused on the company’s collaboration with China Mobile in the country’s Fujian province. China Mobile Fujian has about 30 million or more online subscribers, which is about 70 percent of the market share in the province, according to an announcement by the company last year (https://ibn.fm/PkXvC). The mutual effort between the two companies relates to the buildup of 5G wireless network services in China, and the resources of FingerMotion SMS subsidiary JiuGe. “During the quarter we were aggressive in rolling out our collaboration with China Mobile in the Fujian province. We had to reallocate our resources into telecom which slowed the spectacular revenue growth in SMS that we had seen in the past,” Shen stated, noting that SMS texting services and multimedia MMS audio and video services have been the reason for the Telecommunications Products and Services business sector’s success. FingerMotion reported it had $1,116,448 in cash, a working capital surplus of $5,489,655 and a positive shareholders equity of $5,667,780 at the end of the quarter. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Personal knowledge management involves creating systems, adding context and making information easy to surface when needed
• The customizable, user-friendly Pluaris platform assists users with reading and analyzing textual data and so much more
• Nowigence is focused on simplifying the challenges of learning

The idea of personal knowledge management (“PKM”) systems is gaining traction, with a growing number of individuals and companies recognizing the importance of managing information more efficiently for more successful outcomes. Seeing an opportunity to provide critical support in this quest for knowledge management, Nowigence Inc. (NOWG) has created Pluaris(TM), a cloud-based app that automates reading and analysis of textual data so users can learn more in less time while uncovering hidden insights and staying on top of the information they need to know. “Personal knowledge management is the concept of creating a process or system for collecting and storing information for future use,” explains a recent Search Engine Journal article (https://ibn.fm/4239C). “It’s different from how most of us currently collect digital information, which could more accurately be described as hoarding — accumulating hundreds of bookmarked articles, highlighted book passages, and jotted down statistics. “Digital hoarding doesn’t help you use the information you’re collecting; it makes it harder,” the article continued. “Personal knowledge management, on the other hand, involves creating systems, adding your own context, and making information easy to surface when you need to reference it.” That’s just the beginning of what Nowigence’s Pluaris enables users to do. The customizable, user-friendly platform assists users with reading and analysis of textual data — and so much more (https://ibn.fm/YUxHC). Using artificial intelligence and machine learning, Pluaris automatically analyzes the content it reads by extracting summary points and segregating them as key highlights and the reasons for action, called drivers. These drivers then lay the foundation for cause-and-effect analysis designed to provide readers with key information to help in data gathering and problem solving. Pluaris also labels answers to the most frequently asked questions about topics, such as who, what, where, when, why, how, and how much. It identifies categories and discovers connections. Of course, being able to explore and identify information when it is needed is crucial. Pluaris includes Ask Me, a Google-like search feature, that finds and retrieves information. However, unlike Google, Pluaris is able to search through a person’s internal knowledge base in drives, instant messaging, enterprise tools or other data systems when they are connected with the platform. Nowigence is focused on simplifying the challenges of learning. By integrating state-of-the-art data processing techniques in an intuitive interface at an affordable subscription price, Pluaris puts the power of data science into the hands of consumers. For more information, visit the company’s website at www.Nowigence.com. NOTE TO INVESTORS: The latest news and updates relating to Nowigence are available in the company’s newsroom at https://ibn.fm/NOW

• Diabetes tech market expanded in 2021 due to new users, growing demand for CGM devices, coverage of CGM devices by CMS
• Diabetes is a growing problem in the US. According to CDC, roughly 1 in 10 Americans have diabetes, and 1 in 3 have pre-diabetes
• NMRD currently commercializing the sugarBEAT(R) non-invasive and flexible continuous glucose monitor
• Company recently completed initial shipment to UK licensee

While most medical technology businesses faced COVID-19-related restrictions (https://ibn.fm/NJbOa), Nemaura Medical (NASDAQ: NMRD), a medical technology company that develops affordable diagnostic and digital tools for diabetes management, is favorably positioned in the rapidly growing diabetes tech market with sugarBEAT(R) – a wearable, non-invasive and flexible Continuous Glucose Monitor (“CGM”) designed to help diabetes patients manage glucose levels. Diabetes is a significant concern in the United States, according to a report released by the Center for Disease Control (“CDC”) that provides statistics across ethnicities, ages, education levels, and regions (https://ibn.fm/Ch1HI). According to the report, 34.2 million Americans – roughly 10 percent – have diabetes, and approximately one in three have pre-diabetes. “CDC is working to reverse the epidemic by helping to identify people with pre-diabetes, prevent type 2 diabetes and diabetes complications, and improve the health of all people with diabetes,” reads the report. “Through the National DPP’s evidence-based, affordable lifestyle change program, adults with pre-diabetes learn to make healthy changes that can cut their risk of type 2 diabetes by as much as 58% (71% for those over 60 years).” Controlling insulin is an essential part of the lifestyle changes required to manage and prevent diabetes, according to the US National Institute of Health (“NIH”) (https://ibn.fm/z5jJe). Accordingly, the medtech industry has grown considerably to meet the demand for insulin-monitoring equipment such as insulin pumps and CGM devices. While most businesses faced severe business restraints in 2021, the diabetes tech space had an eventful year with highlights that included climbing user numbers, expansion of coverage for glucose monitoring devices by the Centers for Medicare & Medicaid Services (“CMS”), and bullish analyst projections that forecast increased adoption of diabetes tech devices in 2022 and beyond. NMRD is currently in the process of commercializing its sugarBEAT(R) non-invasive, flexible, and affordable CGM device. With actionable insights from real-time glucose monitoring, sugarBEAT(R) is designed to help diabetic and pre-diabetic people prevent, manage, and reverse diabetes symptoms. As part of its marketing strategy, NMRD recently completed an initial shipment of sugarBEAT(R) devices to MySugarWatch Limited, its UK licensee. MySugarWatch Limited intends to market sugarBEAT(R) via a subscription-based diabetes coaching and management service that targets over 4.9 million diabetics and 13.6 million people with an increased risk of contracting Type 2 diabetes in the UK (https://ibn.fm/OdNBO). “This initial shipment of sugarBEAT(R) CGM devices to our UK licensee allows the Company to now recognize revenue for the first time in our corporate history and is a true milestone in our development and growth,” said Nemaura CEO, Dr. Faz Chowdhury. “Starting in the UK, patients with Type 2 diabetes can now benefit from a less invasive glucose monitoring option that should improve patient lifestyle, adherence, and outcome.” Founded in 2011, NMRD initially developed a single platform technology to measure blood markers at the skin’s surface. The Company has since evolved into the wearables space at the intersection of global diabetes, pre-diabetes, and weight loss device markets. With diabetes and obesity on the rise, NMRD is dedicated to addressing the growing need for flexible, affordable glucose monitoring solutions that help prevent, manage, and reverse diabetes and pre-diabetic conditions. For more information, visit the company websites at www.NemauraMedical.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• Lexaria received independent review board approval for its HYPER-H21-4 human clinical study for hypertension treatment
• The stage is also set for other R&D programs for the 2022 calendar year, including HOR-A22-1, DEM-A22-1, RHEUM-A22-1 and DIAB-A22-1
• All of these 2022 R&D programs are fully funded, with Lexaria having raised approximately $15 million over the 2021 calendar year
• Lexaria believes that these programs will build significant value for its stakeholders and pursue policies for substantial improvements to human health

In late 2021, Lexaria Bioscience (NASDAQ: LEXX) announced several new and ongoing R&D programs for its patented DehydraTECH(TM) technology. While making the announcement, Chris Bunka, the Chief Executive Officer (“CEO”), noted that Lexaria would continue to see significant milestones in utilizing DehydraTECH-CBD, focusing on heart disease and hypertension. “Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart disease and hypertension; and separately, for oral nicotine delivery as an alternative to smoking,” noted Mr. Bunka. “We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for characteristics and potential treatment options for hormone replacement, dementia, rheumatoid disease, and diabetes,” he added (https://ibn.fm/0HA7M). It received independent review board approval in what marks a significant milestone for its 2022 R&D program. The approval comes in less than two months after Lexaria announced that it was readying the study protocols for its HYPER-H21-4 study, its fourth recent human clinical study, and its most ambitious one yet (https://ibn.fm/aurm0). The approval sets the stage for the HYPER-H21-4 study that could define Lexaria’s future. HOR-A22-1 study, scheduled to start in April 2022, will evaluate DehydraTECH’s ability to enhance the delivery characteristics of estrogen. DEM-A22-1, expected to begin in July 2022, will evaluate DehydraTECH-CBD with and without nicotine for the potential treatment of dementia. Lexaria also plans to execute on the RHEUM-A22-1 and DIAB-A22-1 studies, scheduled for October and November, respectively, in a move that is intended to build significant value for all its stakeholders while also pursuing policies for substantial improvements to human health. All the R&D for the 2022 calendar year is fully funded, having raised approximately $15 million in funding over the 2021 calendar year. Lexaria is confident that data from the studies will support the company’s plans to enter regulatory pathways, which, it anticipates, will result in the regulatory approval to use DehydraTECH-CBD for the treatment of hypertension and possibly other types of cardiovascular disease. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• SRAX’s performance goes from strength to strength; company announced revenue guidance expecting revenues of $11.5 million for the first quarter and full-year revenues of $46M – $48M.
• Company’s SaaS platform Sequire expected to continue to drive growth and remain instrumental to performance.
• As go-to data provider for investors and public companies, SRAX stays committed to innovating on product, sales, and marketing, which all translates into increased revenue.

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, has announced revenue guidance for 2022, anticipating another strong period ahead. The company expects revenues of $11.5 million for the first quarter, a 111% increase over Q1 2021 revenue. The full-year revenues are expected to be $46M – $48M, an increase of 46% – 52% over 2021 unaudited revenue of approximately $31.5M. In addition, the company announced that the Q4 2021 booking meets expectations (https://ibn.fm/PJKY8). With solutions built to bring clarity and make the digital space more transparent, SRAX aims to deliver unbiased data and reveal analytics for companies to manage ROI from investor relations programs and corporate communication firms. The company’s growth remains closely linked to Sequire, its SaaS platform. Last year the platform grew both in subscribers and functionality, resulting in considerable revenue growth and customer renewals. This year Sequire has a number of significant releases that will continue to enhance the platform’s value. Sequire’s success is driven by its focus on delivering solutions that solve important pain points for public companies. To stay competitive in today’s environment, companies need to better communicate with their shareholders and the broader investment community. As a data analytics platform designed for public companies to track essential data, SRAX provides unique opportunities for investors and public companies to connect and communicate through its Sequire SaaS platform. Sequire provides users with data that help them understand market activity and develop insights to engage their investor base. With this platform, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. SRAX has also expanded its model to include additional value-added services from the investor relations space, such as their preeminent industry conferences. The company owns LD Micro, a respected conference provider targeted at small and micro-cap markets. “Our team did excellent work in 2021, meeting and exceeding our guidance. The nature of our annual contracts provides us exceptional visibility into revenue,” said Christopher Miglino, Founder and CEO of SRAX. “We are projecting that we will have our largest quarter ever in Q1 of 2022. With an acceleration in sales at the end of Q4, we are very comfortable in providing a full-year, 2022 guidance of $46-$48M,” added Miglino. SRAX has seen its financial performance go from strength to strength over the past year, with recently reported results revealing exceptional revenue growth. Its remarkable performance and growth trajectory appear to have contributed to the increased investors’ interest, with several hedge funds and other institutional players adding to their stakes in the company (https://ibn.fm/J6IAL). For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Over 466 million people current suffer from disabling hearing loss with a further 1.1 billion people at risk of suffering hearing damage
• Elevated device cost, poor after-sales service, and a lack of access to proper healthcare have led to only 14% of the 48 million American with hearing loss to currently use hearing aid devices
• InnerScope Hearing Technologies has sought to address this issue with its affordable direct-to-consumer sales model
• InnerScope CEO, Matthew Moore presented at the Emerging Growth Conference on January 5th, updating shareholders and investors on the company’s latest operational highlights

As of March 2019, the World Health Organization (“WHO”) estimated that disabling hearing loss affected around 466 million people across the globe, out of whom 34 million were children. Moreover, the WHO forecast that up to 1.1 billion people between the ages of 12 to 35 years globally were subject to hearing loss risk, largely due to constant noise exposure (https://ibn.fm/ftcaw). InnerScope Hearing Technologies (OTC: INND), a manufacturer and distributor/retailer of DTC, FDA registered, Bluetooth app-controlled hearing aids and personal sound amplifier products (“PSAPs”), has long sought to become a leader in the direct-to-consumer hearing aid market, with the goal in mind to provide affordable hearing to the tens of millions of Americans suffering from hearing loss today. Elevated device costs, problems associated with devices such as post-purchase services, battery problems, and maintenance issues, along with poor access to adequate healthcare, are all factors that have historically contributed towards restricting the growth of the global hearing aid market. In fact, a recent White House Fact Sheet revealed that the elevated cost of hearing aids had led to only 14% of the approximately 48 million Americans with hearing loss using them (https://ibn.fm/pEwQI). In addition, a heavily concentrated marketplace – with the four largest hearing aid manufacturers controlling upwards of 84% of the market – has also contributed to the elevated pricing for the devices. Nonetheless, the global hearing aid market is estimated to display a strong underlying growth trend over the coming years, with a forecast 6.6% CAGR between 2021-2028. Through its dedicated online portal, www.iHeardirect.com, InnerScope has looked to provide consumers with affordable, Bluetooth app-controlled, self-adjusting hearing technology in a prompt and affordable manner. The company’s HearIQ App for iPhone and Android has been designed to include a free self-check hearing test, providing billions of people worldwide with the means to detect and self-diagnose early-onset hearing loss. Meanwhile, the company’s proprietary hearing technology provides customers with the ability to personalize each hearing device to their hearing needs in under 10 minutes. InnerScope Hearing Technologies recently acquired HearingAssist, a long-established leader in the direct-to-consumer hearing aid market and Walmart’s largest hearing aid supplier, for a gross consideration of $10 million, with the express intent to create a “powerful disruptive company in the global hearing device market.” At the time of acquisition, Matthew Moore, President and CEO of InnerScope, stated, “Today is a tremendous milestone for InnerScope. I’m delighted to welcome the HearingAssist team, who share our passion for providing convenient and affordable hearing products for the tens of millions of Americans who suffer from hearing loss. The HearingAssist acquisition is another meaningful step in advancing our strategy to grow as a leader and innovator in the direct-to-consumer hearing aid market.” Separately, InnerScope Hearing has revealed that Matthew Moore was invited to present at the Emerging Growth Conference, a live interactive online event that took place on Wednesday 5^th January, which allowed InnerScope’s existing shareholders and the investment community to interact with InnerScope’s CEO in real-time. Interested investors. You can watch Moore presentation by clicking on the link: https://www.youtube.com/watch?v=QuAndXZLbMk Moore’s presentation highlighted InnerScope’s two recent direct-to-consumer hearing aid company acquisitions with iHear Medical Inc., its 40+ patents, and its iHearTest, the only FDA-cleared, in-home hearing test on the market and sold at CVS Pharmacy’s; and HearAssist II LLC., Walmart’s largest hearing aid supplier. In addition, Moore discussed InnerScope’s 2022 growth trajectory with these pivotal acquisitions and a key partnership with Atlazo Inc., a leader in intelligent semiconductor solutions, to develop new types of unprecedented artificial intelligence hearing products. For more information, visit the company’s website at www.INND.com and the company’s e-commerce websites www.iHeardirect.com and www.HearingAssist.com NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND